AbbVie Faces 1st Antitrust Suit Over Humira 'Patent Thicket'

By Jeff Overley · March 18, 2019, 11:11 PM EDT

AbbVie Inc.'s colossal "patent thicket" for its $20-billion-per-year immunosuppressant Humira has empowered it to block less-expensive biosimilars in violation of numerous antitrust laws, according to a first-of-its-kind suit launched Monday....

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Complaint

Case Information

Case Title

In Re: Humira (Adalimumab) Antitrust Litigation

Case Number

Court

Illinois Northern

Nature of Suit

410(Anti-Trust)

Date Filed

March 18, 2019

Recent Articles By Jeff

July 05, 2024
How Reshaped Circuit Courts Are Faring At The High Court
July 05, 2024
The Funniest Moments Of The Supreme Court's Term
June 29, 2024
Chevron's End Is Just The Start For Energized Agency Foes
June 17, 2024
Teva, DOJ Signal Key Kickback Case May Fizzle At 1st Circ.
March 29, 2024
Hogan Lovells Vet's High Court Debut A Study In Contrasts
January 29, 2024
The Top Attys In Clinton's Impeachment Trial, 25 Years Later
January 18, 2024
'Chaos' Warning Resonates As Justices Mull Chevron's Fate
January 01, 2024
Appellate Outlook: Circuit Splits & Hot Topics To Track In 2024
December 09, 2023
Circuit-By-Circuit Guide To 2023's Most Memorable Moments
November 09, 2023
Paul Clement's Big Idea: Overrule Chevron, Ease Polarization